An Sp1 modulated regulatory region unique to higher primates regulates human androgen receptor promoter activity in prostate cancer cells

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Hay, Colin W ^a   Hunter, Irene ^a   MacKenzie, Alasdair ^a   McEwan, Iain J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PUR ALPHA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; 5' UNTRANSLATED REGION; PROTEIN BINDING;

5' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROMOTER REGION; PROSTATE CANCER CELL LINE; REGULATORY SEQUENCE; ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; GORILLA GORILLA; MALE; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; ORANGUTAN; PAN TROGLODYTES; PHYSIOLOGY; PROSTATE TUMOR; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

5' UNTRANSLATED REGIONS; ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GORILLA GORILLA; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PAN TROGLODYTES; PONGO; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SEQUENCE HOMOLOGY, NUCLEIC ACID; SP1 TRANSCRIPTION FACTOR;

EID: 84948658683     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139990     Document Type: Article

References (62)

1. WHO. Cancer Fact Sheet, GLOBOCAN 2008. 2008.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61: 1079-1092. doi: 10.1016/j.eururo. 2012.02.054 PMID: 22424666
3. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004; 25: 276-308. PMID: 15082523
4. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol. 2007; 21: 2855-2863. PMID: 17636035
5. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinog. 2011; 10: 20-3163. 83937. Epub 2011 Aug 23. doi: 10.4103/1477-3163.83937 PMID: 21886458
6. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010; 24: 1967-2000. doi: 10.1101/gad.1965810 PMID: 20844012
7. Azzouni F, Mohler J. Biology of castration-recurrent prostate cancer. Urol Clin North Am. 2012; 39: 435-452. doi: 10.1016/j.ucl.2012.07.002 PMID: 23084522
8. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005; 23: 8253-8261. PMID: 16278481
9. Green SM, Mostaghel EA, Nelson PS. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol. 2012; 360: 3-13. doi: 10.1016/j.mce.2011.09.046 PMID: 22453214
10. Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV, Gurova KV. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate. 2007; 67: 1801-1815. PMID: 17935158
11. Wu D, Zhang C, Shen Y, Nephew KP, Wang Q. Androgen receptor-driven chromatin looping in prostate cancer. Trends Endocrinol Metab. 2011; 22: 474-480. doi: 10.1016/j.tem.2011.07.006 PMID: 21889355
12. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev. 2007; 28: 778-808. PMID: 17940184
13. He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, et al. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014; 111: 18261-18266. doi: 10.1073/pnas.1421415111 PMID: 25489091
14. Wu D, Sunkel B, Chen Z, Liu X, Ye Z, Li Q, et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res. 2014; 42: 3607-3622. doi: 10.1093/nar/gkt1382 PMID: 24423874
15. Shah S, Prasad S, Knudsen KE. Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Res. 2012; 72: 1248-1259. doi: 10.1158/0008-5472. CAN-11-0943 PMID: 22258452
16. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008; 8: 440-448. doi: 10.1016/j.coph.2008.07.005 PMID: 18674639
17. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001; 61: 1919-1926. PMID: 11280747
18. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001; 61: 3550-3555. PMID: 11325816
19. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res. 2007; 35: 2767-2776. PMID: 17426117
20. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014; 6: 254ra125. doi: 10.1126/scitranslmed.3009448 PMID: 25232177
21. Urbanucci A, Sahu B, Seppala J, Larjo A, Latonen LM, Waltering KK, et al. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene. 2012; 31: 2153-2163. doi: 10.1038/onc.2011.401 PMID: 21909140
22. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009; 69: 8141-8149. doi: 10.1158/0008-5472.CAN-09-0919 PMID: 19808968
23. Decker KF, Zheng D, He Y, Bowman T, Edwards JR, Jia L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. Nucleic Acids Res. 2012; 40: 10765-10779. doi: 10.1093/nar/gks888 PMID: 23019221
24. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138: 245-256. doi: 10.1016/j.cell.2009. 04.056 PMID: 19632176
25. Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 2013; 23: 35-47. doi: 10.1016/j.ccr.2012.11.010 PMID: 23260764
26. Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, et al. Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol. 1997; 31: 216-219. PMID: 9076469
27. Takane KK, McPhaul MJ. Functional analysis of the human androgen receptor promoter. Mol Cell Endocrinol. 1996; 119: 83-93. PMID: 8793857
28. Faber PW, van Rooij HC, Schipper HJ, Brinkmann AO, Trapman J. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J Biol Chem. 1993; 268: 9296-9301. PMID: 8486625
29. Wang LG, Ferrari AC. Mithramycin Targets Sp1 and The Androgen Receptor Transcription Level-Potential Therapeutic Role in Advanced Prostate Cancer. 2006; 2: 19-31.
30. Chen S, Supakar PC, Vellanoweth RL, Song CS, Chatterjee B, Roy AK. Functional role of a conformationally flexible homopurine/homopyrimidine domain of the androgen receptor gene promoter interacting with Sp1 and a pyrimidine single strand DNA-binding protein. Mol Endocrinol. 1997; 11: 3-15. PMID: 8994183
31. Courey AJ, Tjian R. Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell. 1988; 55: 887-898. PMID: 3142690
32. Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat. 2010; 192: 275-283. doi: 10.1016/j.aanat.2010.07.010 PMID: 20810260
33. Ko S, Shi L, Kim S, Song CS, Chatterjee B. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol. 2008; 22: 273-286. PMID: 17975021
34. Hay CW, Watt K, Hunter I, Lavery DN, MacKenzie A, McEwan IJ. Negative Regulation of the Androgen Receptor Gene Through a Primate-Specific Androgen Response Element Present in the 5' UTR. Horm Cancer. 2014.
35. Wang LG, Ossowski L, Ferrari AC. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line. Oncogene. 2004; 23: 5175-5184. PMID: 15156193
36. Wang LG, Johnson EM, Kinoshita Y, Babb JS, Buckley MT, Liebes LF, et al. Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex. Cancer Res. 2008; 68: 2678-2688. doi: 10.1158/0008-5472.CAN-07-6017 PMID: 18413735
37. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, et al. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer. EMBO J. 2015; 34: 502-516. doi: 10. 15252/embj.201490306 PMID: 25535248
38. Hay CW, McEwan IJ. The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One. 2012; 7: e32514. doi: 10.1371/journal. pone.0032514 PMID: 22403669
39. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983; 11: 1475-1489. PMID: 6828386
40. Grossmann ME, Lindzey J, Kumar MV, Tindall DJ. The mouse androgen receptor is suppressed by the 5'-untranslated region of the gene. Mol Endocrinol. 1994; 8: 448-455. PMID: 8052266
41. Grossmann ME, Tindall DJ. The androgen receptor is transcriptionally suppressed by proteins that bind single-stranded DNA. J Biol Chem. 1995; 270: 10968-10975. PMID: 7738038
42. Steiper ME, Young NM. Primate molecular divergence dates. Mol Phylogenet Evol. 2006; 41: 384-394. PMID: 16815047
43. Mizokami A, Yeh SY, Chang C. Identification of 3',5'-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol. 1994; 8: 77-88. PMID: 8152432
44. Hay CW, Ferguson LA, Docherty K. ATF-2 stimulates the human insulin promoter through the conserved CRE2 sequence. Biochim Biophys Acta. 2007; 1769: 79-91. PMID: 17337306
45. Snyder RC, Ray R, Blume S, Miller DM. Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters. Biochemistry. 1991; 30: 4290-4297. PMID: 1827033
46. Johnson EM, Daniel DC, Gordon J. The pur protein family: genetic and structural features in development and disease. J Cell Physiol. 2013; 228: 930-937. doi: 10.1002/jcp.24237 PMID: 23018800
47. Inoue T, Leman ES, Yeater DB, Getzenberg RH. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate. 2008; 68: 1048-1056. doi: 10.1002/pros.20764 PMID: 18386260
48. Sankpal UT, Goodison S, Abdelrahim M, Basha R. Targeting Sp1 transcription factors in prostate cancer therapy. Med Chem. 2011; 7: 518-525. PMID: 22022994
49. Yuan H, Gong A, Young CY. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis. 2005; 26: 793-801. PMID: 15661808
50. Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Prostate. 2010; 70: 179-189. doi: 10.1002/pros.21051 PMID: 19790234
51. Su W, Jackson S, Tjian R, Echols H. DNA looping between sites for transcriptional activation: self-association of DNA-bound Sp1. Genes Dev. 1991; 5: 820-826. PMID: 1851121
52. Tretiakova A, Steplewski A, Johnson EM, Khalili K, Amini S. Regulation of myelin basic protein gene transcription by Sp1 and Puralpha: evidence for association of Sp1 and Puralpha in brain. J Cell Physiol. 1999; 181: 160-168. PMID: 10457364
53. White MK, Johnson EM, Khalili K. Multiple roles for Puralpha in cellular and viral regulation. Cell Cycle. 2009; 8: 1-7. PMID: 19182532
54. Tewari AK, Yardimci GG, Shibata Y, Sheffield NC, Song L, Taylor BS, et al. Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biol. 2012; 13: R88. doi: 10.1186/gb-2012-13-10-r88 PMID: 23034120
55. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007; 67: 967-975. PMID: 17283128
56. Malek A, Nunez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, et al. Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One. 2012; 7: e35130. doi: 10.1371/journal.pone.0035130 PMID: 22545098
57. Wang LG, Liu XM, Chiao JW. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate. Carcinogenesis. 2006; 27: 2124-2132. PMID: 16704988
58. Beklemisheva AA, Feng J, Yeh YA, Wang LG, Chiao JW. Modulating testosterone stimulated prostate growth by phenethyl isothiocyanate via Sp1 and androgen receptor down-regulation. Prostate. 2007; 67: 863-870. PMID: 17431886
59. Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, Lou HX. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochem Pharmacol. 2008; 75: 2112-2121. doi: 10.1016/j.bcp.2008.03.005 PMID: 18430409
60. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res. 2007; 67: 2816-2823. PMID: 17363604
61. Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene. 2000; 19: 1924-1932. PMID: 10773882
62. Song K, Wang H, Krebs TL, Kim SJ, Danielpour D. Androgenic control of transforming growth factorbeta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res. 2008; 68: 8173-8182. doi: 10.1158/0008-5472.CAN-08-2290 PMID: 18829577